



CGMP BELLWETHER LABORATORY

Nuclear Innovation for the Next Generation of Isotopes

TerraPower Isotopes® is building its flagship cGMP actinium-225 manufacturing facility with HRP Group in the Bellwether District of Philadelphia, Pennsylvania. TerraPower Isotopes’ actinium-225 is transforming the fight against cancer by supporting the development of targeted alpha therapy (TAT) cancer treatments. This new facility will dramatically accelerate TPI’s manufacturing scale, increasing annual isotope production capacity by 20-fold.

Establishing a new, large-scale, East Coast cGMP facility, along with current production capacity in TPI’s laboratory in Everett, Washington, positions TPI as the premier, global distributor of actinium-225 for growing TAT drug programs.

Fast Facts

- + Project Developers – HRP and Orchestra Life Sciences
- + Construction Jobs – ~500
- + Permanent Jobs – ~250
- + cGMP Isotope Production – Actinium-225
- + Start of Manufacturing Operations – 2029



Enhancing Philadelphia's Medical Corridor

TPI completed an extensive, nationwide site-selection process to determine the most viable location for this new manufacturing facility. Over 350 potential sites were put forward, 49 included site visits across eight metropolitan areas.

The benefits of a strong medical research community throughout the region, including an exceptional talent pool, and the site-specific benefits of the Bellwether location, make Philadelphia an ideal location for this cutting-edge isotope production facility.

Expanding the Global Actinium-225 Supply Chain

TerraPower Isotopes is advancing new medical applications to enable potential lifesaving cancer therapies. The TPI team is utilizing proven methods to extract research grade actinium-225 (Ac-225), free of the isotopic impurities of actinium, which are being applied to new medical applications by drug developers that potentially target and treat cancer.

TPI is increasing the scarce global supply of Ac-225 to support pharmaceutical companies' cancer research and development efforts. Ac-225 is currently being utilized in human clinical trials around the world. TPI's cGMP Bellwether Production will further expand Ac-225 supply reliability, cGMP quality, and production levels ready to support commercially available drugs.



TERRAPOWER ISOTOPES' ACTINIUM-225 IS CURRENTLY BEING UTILIZED IN HUMAN CLINICAL TRIALS AROUND THE WORLD.



Project Milestones

The project features a multi-year buildout, with production of cGMP actinium-225 beginning in 2029.

TPI is investing \$450 million to establish the manufacturing facility, which will create 225 new-full time jobs over the next three years.